Recent Updates
Recently added Catalysts
NMTC Positive Sentiment Score: 70/100

NeuroOne to Participate in the 36th Annual Roth Conference

Key Takeaway: NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has announced its participation in the upcoming 36th Annual Roth Conference from March 17-19, 2024, in Dana Point, California. CEO Dave Rosa and CFO Ron McClurg will hold individual meetings with institutional investors and analysts. The company aims to enhance surgical care for patients with neurological disorders and may explore various applications, including artificial intelligence. The participation in this conference highlights NeuroOne's commitment to innovation in the medical technology field.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prestigious investment conference can enhance visibility.
  • One-on-one meetings with institutional investors may attract funding.
  • Focus on improving surgical care options may appeal to potential investors.

Full Press Release Details

EDEN PRAIRIE, Minn., March 08, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the 36th Annual Roth Conference being held March 17-19, 2024 in Dana Point, California. Chief Executive Offer Dave Rosa and Chief Financial Officer Ron McClurg will host one-on-one meetings with institutional investors and analysts on Monday, March 18th and Tuesday, March 19th.
Location: The Ritz Carlton, Laguna Niguel in Dana Point, California.
R egistration: Available on the conference website .
1x1 meetings: Investors may request a meeting by contacting a Roth representative at 800.678.9147 or by contacting NeuroOne investor relations .
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.

Tags

NeuroOne Medical Technologies
36th Annual Roth Conference

Frequently Asked Questions

When is NeuroOne participating in the Roth Conference?

NeuroOne will participate in the 36th Annual Roth Conference from March 17-19, 2024.

Where is the 36th Annual Roth Conference held?

The conference takes place at The Ritz Carlton, Laguna Niguel in Dana Point, California.

Who will represent NeuroOne at the conference?

NeuroOne will be represented by CEO Dave Rosa and CFO Ron McClurg.

How can investors request one-on-one meetings?

Investors can request meetings by contacting a Roth representative at 800.678.9147.

What neurological disorders does NeuroOne focus on?

NeuroOne focuses on epilepsy, Parkinson's, chronic pain, and more neurological disorders.

Last updated: Mar 8, 2024